Clinical and regulatory intelligence for HER2-positive Upper Tract Urothelial Carcinoma with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.

Signals: 1
Catalysts: 0
Assets: 1

Relevant assets

Tislelizumab →

Relevant companies

No related entities indexed yet.

Recent signals(1)

ClinicalJuly 15, 2026

Tislelizumab and Disitamab-Vedotin Show Promise in Neoadjuvant Therapy for HER2-positive UTUC

A clinical trial is investigating the efficacy and safety of combining tislelizumab and disitamab-vedotin as neoadjuvant therapy for high-risk HER2-positive upper tract urothelial carcinoma.

Upcoming catalysts

No catalysts indexed for this entity yet.

Therapeutic areas

HER2-positive Upper Tract Urothelial Carcinoma →

Oncology →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.